STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ARPA-H announced Thursday it will spend up to $160 million on a new program called THRIVE aimed at advancing custom gene-editing treatments for rare diseases
- THRIVE will back seven distinct teams, each pursuing gene-editing approaches for rare conditions affecting different organ systems
- Each funded team faces a deadline of launching clinical trials by year three of the program, though ARPA-H noted some teams may begin trials much sooner
- ARPA-H is positioning the initiative within its 'moonshot' mandate, framing custom gene editing for rare diseases as a priority area for accelerated federal investment
Why it matters: With a hard three-year clinical-trial deadline and $160 million spread across seven teams, ARPA-H is compressing the typical timeline for rare-disease gene therapy development — a direct federal bet that custom gene editing can move from research to human trials on a moonshot pace, with rare-disease patients the named beneficiaries.
